Title: Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group
Abstract: CancerVolume 54, Issue 9 p. 1802-1813 ArticleFree Access Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group Mitchell H. Gail MD, PHD, Corresponding Author Mitchell H. Gail MD, PHD National Institutes of Health, National Cancer Institute, Bethesda, MarylandNational Cancer Institute, Blair Building, Room 3A05, Bethesda, MD 20205===Search for more papers by this authorRobert T. Eagan MD, Robert T. Eagan MD Mayo Clinic, Rochester, MinnesotaSearch for more papers by this authorRonald Feld MD, Ronald Feld MD Princess Margaret Hospital, Rochester, MinnesotaSearch for more papers by this authorRobert Ginsberg MD, Robert Ginsberg MD Toronto General Hospital, Toronto, Ontario, CanadaSearch for more papers by this authorBrian Goodell MD, Brian Goodell MD Fred Hutchinson Cancer Center, Seattle, WashingtonSearch for more papers by this authorLucius Hill MD, Lucius Hill MD Swedish Medical Center, Seattle, WashingtonSearch for more papers by this authorE. Carmack Holmes MD, E. Carmack Holmes MD University of California, School of Medicine, Los Angeles, CaliforniaSearch for more papers by this authorJohn M. Lukeman MD, John M. Lukeman MD M. D. Anderson Hospital, University of Texas System Cancer Center, Houston, TexasSearch for more papers by this authorClifton F. Mountain MD, Clifton F. Mountain MD M. D. Anderson Hospital, University of Texas System Cancer Center, Houston, TexasSearch for more papers by this authorRobert K. Oldham MD, Robert K. Oldham MD Division of Oncology, Vanderbilt University, Nashville, TennesseeSearch for more papers by this authorF. G. Pearson MD, F. G. Pearson MD Toronto General Hospital, Toronto, Ontario, CanadaSearch for more papers by this authorPeter W. Wright MD, Peter W. Wright MD Swedish Medical Center, Seattle, WashingtonSearch for more papers by this authorWilliam H. Lake Jr, William H. Lake Jr Information Management Services, Rockville, MarylandSearch for more papers by this authorThe Lung Cancer Study Group, The Lung Cancer Study Group Members of the Lung Cancer Study Group include: E. C. Holmes∥︁ ∥︁ (Group Chairman), W. F. Coulson, K. P. Ramming, and T. H. Weisenburger (University of California, Los Angles, CA); Z. Petrovich (Wadsworth Veterans Hospital, Los Angeles, CA); R. T. Eagan,∥︁ ∥︁ R. E. Lee, W. S. Payne, R. E. Ritts, and L. Weiland (Mayo Clinic, Rochester, MN); C. F. Mountain,∥︁ ∥︁ H. T. Barkley, O. H. Frazier, K. Hermes, E. Hersh, and M. Valdivieso (University of Texas System Cancer Center, M. D. Anderson Hospital, Houston, TX); L. D. Hill,∥︁ ∥︁ M. D. Hafermann, and E. Morgan (Mason Clinic, Seattle, WA); B. Goodell, ∥︁ ∥︁ and K. E. Hellstrom (Hutchinson Cancer Center, Seattle, WA); C. Bagley, L. P. Johnson, H. Kellogg, P. W. Wright,∥︁ ∥︁ and R. D. Pinkman (Swedish Medical Center, Seattle, WA); T. D. Ivey (University Hospital, Seattle, WA); S. Hammar (Virginia Mason Hospital, Seattle, WA); W. Nelems (St. Paul's Hospital, Vancouver, British Columbia, Canada); R. Feld,∥︁ ∥︁ D. Bergsagel, T. C. Brown, J. Curtis, C. Keen, J. F. Pringle, I. Quirt, and L. Yeoh (Princess Margaret Hospital, Toronto, Ontario, Canada); M. Blackstein, and M. Goldberg Mount Sinai Hospital, Toronto, Ontario, (Canada); F. G. Pearson,∥︁ ∥︁ R. Ginsberg,∥︁ ∥︁ D. W. Chamberlain, J. Cooper, W. Evans, and T. Todd (Toronto General Hospital, Toronto, Ontario, Canada); M. Baker (Toronto Western Hospital, Toronto, Ontario, Canada); R. I. Mitchell, and D. P. Jones (Wellesley Hospital, Toronto, Ontario, Canada); R. K. Oldham,∥︁ ∥︁ J. T. Forbes, F. A. Greco, D. L. Page, R. Prager, R. L. Richardson, and S. L. Stroup (Vanderbilt University, Nashville, TN); J. M. Lukeman,∥︁ ∥︁ and S. M. Sajjad (Pathology Reference Center of UT M. D. Anderson Hospital, Houston, TX); P. Grifone, A. Lebeck, A. Sharpe, and T. Voss (Operations Office, Silver Springs, MD); W. Lake Jr, J. Beach, L. Close, and H. Powell (Information Management Services, Bethesda, MD). Group Statisticians: M. Gail, and L. Rubinstein. Project Officers: W. McGuire, J. Allegra, and G. Witman. Program Director: M. Eisenberger (National Cancer Institute, Bethesda, MD)Search for more papers by this author Mitchell H. Gail MD, PHD, Corresponding Author Mitchell H. Gail MD, PHD National Institutes of Health, National Cancer Institute, Bethesda, MarylandNational Cancer Institute, Blair Building, Room 3A05, Bethesda, MD 20205===Search for more papers by this authorRobert T. Eagan MD, Robert T. Eagan MD Mayo Clinic, Rochester, MinnesotaSearch for more papers by this authorRonald Feld MD, Ronald Feld MD Princess Margaret Hospital, Rochester, MinnesotaSearch for more papers by this authorRobert Ginsberg MD, Robert Ginsberg MD Toronto General Hospital, Toronto, Ontario, CanadaSearch for more papers by this authorBrian Goodell MD, Brian Goodell MD Fred Hutchinson Cancer Center, Seattle, WashingtonSearch for more papers by this authorLucius Hill MD, Lucius Hill MD Swedish Medical Center, Seattle, WashingtonSearch for more papers by this authorE. Carmack Holmes MD, E. Carmack Holmes MD University of California, School of Medicine, Los Angeles, CaliforniaSearch for more papers by this authorJohn M. Lukeman MD, John M. Lukeman MD M. D. Anderson Hospital, University of Texas System Cancer Center, Houston, TexasSearch for more papers by this authorClifton F. Mountain MD, Clifton F. Mountain MD M. D. Anderson Hospital, University of Texas System Cancer Center, Houston, TexasSearch for more papers by this authorRobert K. Oldham MD, Robert K. Oldham MD Division of Oncology, Vanderbilt University, Nashville, TennesseeSearch for more papers by this authorF. G. Pearson MD, F. G. Pearson MD Toronto General Hospital, Toronto, Ontario, CanadaSearch for more papers by this authorPeter W. Wright MD, Peter W. Wright MD Swedish Medical Center, Seattle, WashingtonSearch for more papers by this authorWilliam H. Lake Jr, William H. Lake Jr Information Management Services, Rockville, MarylandSearch for more papers by this authorThe Lung Cancer Study Group, The Lung Cancer Study Group Members of the Lung Cancer Study Group include: E. C. Holmes∥︁ ∥︁ (Group Chairman), W. F. Coulson, K. P. Ramming, and T. H. Weisenburger (University of California, Los Angles, CA); Z. Petrovich (Wadsworth Veterans Hospital, Los Angeles, CA); R. T. Eagan,∥︁ ∥︁ R. E. Lee, W. S. Payne, R. E. Ritts, and L. Weiland (Mayo Clinic, Rochester, MN); C. F. Mountain,∥︁ ∥︁ H. T. Barkley, O. H. Frazier, K. Hermes, E. Hersh, and M. Valdivieso (University of Texas System Cancer Center, M. D. Anderson Hospital, Houston, TX); L. D. Hill,∥︁ ∥︁ M. D. Hafermann, and E. Morgan (Mason Clinic, Seattle, WA); B. Goodell, ∥︁ ∥︁ and K. E. Hellstrom (Hutchinson Cancer Center, Seattle, WA); C. Bagley, L. P. Johnson, H. Kellogg, P. W. Wright,∥︁ ∥︁ and R. D. Pinkman (Swedish Medical Center, Seattle, WA); T. D. Ivey (University Hospital, Seattle, WA); S. Hammar (Virginia Mason Hospital, Seattle, WA); W. Nelems (St. Paul's Hospital, Vancouver, British Columbia, Canada); R. Feld,∥︁ ∥︁ D. Bergsagel, T. C. Brown, J. Curtis, C. Keen, J. F. Pringle, I. Quirt, and L. Yeoh (Princess Margaret Hospital, Toronto, Ontario, Canada); M. Blackstein, and M. Goldberg Mount Sinai Hospital, Toronto, Ontario, (Canada); F. G. Pearson,∥︁ ∥︁ R. Ginsberg,∥︁ ∥︁ D. W. Chamberlain, J. Cooper, W. Evans, and T. Todd (Toronto General Hospital, Toronto, Ontario, Canada); M. Baker (Toronto Western Hospital, Toronto, Ontario, Canada); R. I. Mitchell, and D. P. Jones (Wellesley Hospital, Toronto, Ontario, Canada); R. K. Oldham,∥︁ ∥︁ J. T. Forbes, F. A. Greco, D. L. Page, R. Prager, R. L. Richardson, and S. L. Stroup (Vanderbilt University, Nashville, TN); J. M. Lukeman,∥︁ ∥︁ and S. M. Sajjad (Pathology Reference Center of UT M. D. Anderson Hospital, Houston, TX); P. Grifone, A. Lebeck, A. Sharpe, and T. Voss (Operations Office, Silver Springs, MD); W. Lake Jr, J. Beach, L. Close, and H. Powell (Information Management Services, Bethesda, MD). Group Statisticians: M. Gail, and L. Rubinstein. Project Officers: W. McGuire, J. Allegra, and G. Witman. Program Director: M. Eisenberger (National Cancer Institute, Bethesda, MD)Search for more papers by this author First published: 1 November 1984 https://doi.org/10.1002/1097-0142(19841101)54:9<1802::AID-CNCR2820540908>3.0.CO;2-4Citations: 199 AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract The authors present prognostic information on recurrence and survival for resected Stage I lung cancer patients with squamous cell carcinoma, adenocarcinoma or large cell carcinoma. The data derive from 392 carefully staged patients and include results from the history and physical examination, preoperative laboratory tests, nature of the surgery, complications, initial pathologic findings following surgical resection, and final pathologic review. A simple multivariate model of recurrence, which is used to classify patients into low, intermediate, and high-risk groups, is based on tumor size and location (T1, T2), histologic type (squamous, nonsquamous/mixed) and nodal status (N0, N1). To model survival, the performance status and the presence of empyema, pneumonia, or wound infection were added to the previous factors. Not all factors associated with increased mortality are associated with increased risk of recurrence, and, in particular, postoperative empyema, pneumonia or wound infections carry an increased risk of death only. Serial measurements of performance status and leukocyte count have the potential for monitoring for increased risk of recurrence and death. References 1 Zelen M. Keynote address on biostatistics and data retrieval. Cancer 1973; 4: 31– 42. 2 Lagakos SW. Prognostic factors for survival in inoperable lung cancer. In: MJ Strauss, ed. Lung Cancer Clinical Diagnosis and Treatment. New York: Grune & Stratton, 1977; 271– 280. 3 Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65: 25– 32. 4 Cohan MH, Selawry OS. Bronchogenic carcinoma: Prognostic factors and criteria of response. In: M Staquet, ed. Cancer Therapy: Prognostic Factors and Criteria of Response. New York: Raven Press, 1975; 185– 197. 5 Katlic M, Carter D. Prognostic implications of histology, size and location of primary tumors. In: F Muggia, M Rozencweig, eds. Lung Cancer: Progress in Therapeutic Approach. New York: Raven Press, 1979; 143– 154. 6 American Joint Committee for Cancer Staging and End Results Reporting, Task Force on the Lung: Mountain CF, Carr DT, Martini N, Woolner CB, Raventos A. Manual for classification of cancer by site. Chicago, 1977; 59– 61. 7 Mountain CF, Carr DT. A system for the clinical staging of lung cancer. Am J Roentgenol 1974; 120: 130– 138. 8 Carr DT, Mountain CF. Staging lung cancer. In: MJ Strauss, ed. Lung Cancer Clinical Diagnosis and Treatment. New York: Grune & Stratton, 1977; 151– 161. 9 Mountain CF, Hermes KE. Management implications of surgical staging studies. In: F Muggia, M Rosencweig, eds. Lung Cancer: Progress in Therapeutic Approach. New York: Raven Press, 1979; 233– 242. 10 Martini N, Beattie EJ. Results of surgical treatment in stage I lung cancer. J Thorac Cardiovac Surg 1977; 74: 499– 505. 11 Williams DE, Pairolero PC, David CS et al. Survival of patients surgically treated for stage I lung cancer. J Thorac Cardiovasc Surg 1981; 82: 70– 76. 12 Mountain CF, Gail MH. Surgical adjuvant intrapleural BCG treatment for stage I non-small cell lung cancer: Preliminary report of the National Cancer Institute Lung Cancer Study Group. J Thorac Cardiovasc Surg 1981; 82: 649– 657. 13 Oldham RK, Gail MH, Baker MA et al. Immunologic studies in a double blind randomized trial comparing intrapleural BCG against placebo in patients with resected stage I non-small cell lung cancer. Cancer Immunol Immunother 1982; 13: 164– 173. 14 Culter SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chronic Dis 1958; 8: 699– 712. 15 Thomas DG, Breslow N, Gart JJ. Trend and hemogeneity analyses of proportions and life table data. Comput Biomed Res 1977; 10. 373– 381. 16 Byar DP, Green SB, Dor P et al. A prognostic index for thyroid carcinoma: A study of the EORTC Thyroid Cancer Cooperative Group. Eur J Cancer 1979; 15: 1033– 1041. 17 Gail MH. Evaluating serial cancer marker studies in patients at risk of recurrent disease. Biometrics 1981; 37: 67– 78. 18 Karnofsky DA, Abelmann WH, Craver LF et al. The use of nitrogen mustards in the palliative treatment of cancer. Cancer 1948; 1: 634– 656. 19 McKneally MF, Maver C, Kauel HW. Regional immunotherapy of lung cancer with BCG. Lancet 1976; 21: 377– 379. 20 Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, 1980; 49– 50. 21 Concannon JP, Dalbow MH, Hodgson SE et al. Prognostic value of preoperative carcinoembryonic antigen (CEA) plasmal levels in patients with bronchogenic carcinoma. Cancer 1978; 42: 1477– 1483. 22 Vincent RG, Chu TM, Lane WW. The value of carcinoembryonic antigen in patients with carcinoma of the lung. Cancer 1979; 44: 685– 691. Citing Literature Volume54, Issue91 November 1984Pages 1802-1813 ReferencesRelatedInformation